Comparative Pharmacology
Head-to-head clinical analysis: NORINYL 1 80 28 DAY versus PIRMELLA 1 35.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORINYL 1 80 28 DAY versus PIRMELLA 1 35.
NORINYL 1+80 28-DAY vs PIRMELLA 1/35
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive containing a progestin (norethindrone) and an estrogen (mestranol). Suppresses gonadotropin (FSH and LH) release via negative feedback, inhibiting ovulation. Also induces changes in cervical mucus and endometrium to impede sperm penetration and implantation.
Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that suppresses gonadotropin secretion via negative feedback on the hypothalamic-pituitary-ovarian axis, inhibiting ovulation. Additionally, causes cervical mucus thickening and endometrial atrophy, reducing sperm penetration and implantation.
One tablet (1 mg norethindrone / 80 mcg ethinyl estradiol) orally once daily for 28-day cycle without placebo.
One tablet orally once daily for 21 days, followed by 7 placebo tablets during the withdrawal bleed.
None Documented
None Documented
Norethindrone: terminal elimination half-life of 5.3-10.5 hours; Mestranol (as ethinyl estradiol): terminal half-life of 7-20 hours. Clinically, steady state is achieved after 5-7 days of daily dosing; the half-life supports once-daily dosing for consistent hormonal levels.
Terminal half-life 24–30 hours for ethinyl estradiol; 13–18 hours for norethindrone. Steady state reached after 7–10 days.
Norethindrone is primarily excreted in urine (approximately 60%) and feces (approximately 40%) as glucuronide and sulfate conjugates. Mestranol is metabolized to ethinyl estradiol; ethinyl estradiol and its metabolites are excreted in urine (40%) and feces (60%).
Renal 60–80% as metabolites (glucuronide conjugates), biliary/fecal 10–20%.
Category C
Category C
Oral Contraceptive
Oral Contraceptive